跳至主要内容
临床试验/NCT04821219
NCT04821219撤回不适用

Establishing a Platform for Personalized Approach to the Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

Mayo Clinic0 个研究点开始时间: 2022年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
Mayo Clinic
主要终点
Rate of the successful establishment of pancreatic patient-derived tumoroids (PDT)

研究概览

简要总结

This study is designed to prospectively investigate the feasibility of establishing patient-derived tumoroids (PDT) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach. PDT will be investigated to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish the feasibility of PDT as a platform for a personalized approach to guide multimodality treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years of age.
  • Have an ECOG Performance Status of ≤
  • No evidence of distant metastasis on imaging.
  • Histologic or cytologic proven adenocarcinoma of the pancreas.
  • Providing informed consent prior to enrollment in the trial.

排除标准

  • Failure to obtain additional core needle biopsies for generating PDTs.
  • Females who are pregnant or plan to become pregnant.

结局指标

主要结局

Rate of the successful establishment of pancreatic patient-derived tumoroids (PDT)

时间窗: 2 years

次要结局

  • PDT validation with a comparative analysis of patients' response to neoadjuvant chemotherapy and radiation(2 years)
  • Drug sensitivity and response prediction of radiation therapy in PDT(2 years)
  • Drug sensitivity and response prediction of chemotherapy agents in PDT(2 years)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Panagiotis Z. Anastasiadis

Principal Investigator

Mayo Clinic

相似试验